NMS Informs Cardiff Oncology Of Agreement Termination On May 27, 2026; NMS Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship; NMS Alleges Failure By Cardiff Oncology To Use Commercially Reasonable Efforts For Onvansertib; Cardiff Oncology States NMS Termination Notice Is Ineffective And Will Continue Under Agreement